Nevada PSE bill
This article was originally published in The Tan Sheet
Executive Summary
State lawmakers Feb. 22 introduced A.B. 150 to limit the diversion of pseudoephedrine-containing OTC medicines to methamphetamine production by requiring prescriptions for the products, along with those made with ephedrine and phenylpropanolamine. The Consumer Healthcare Products Association strongly opposes the bill and will express its concerns in Nevada the week of Feb. 26. The bill is modeled after a 2005 Oregon law (1"The Tan Sheet" Aug. 22, 2005, p. 5). The Bush administration has said it will monitor the effectiveness of behind-the counter provisions of the federal Combat Meth Act as well as stricter state strategies (2"The Tan Sheet" June 12, 2006, p. 6)...
You may also be interested in...
Nevada Rx PSE bill dies
Nevada state legislators May 22 rejected a proposal to require pseudoephedrine-containing products to be sold only by prescription. The bill, AB 150, did not receive the necessary two-thirds majority to pass. The Consumer Healthcare Products Association lobbied against the bill after its introduction (1"The Tan Sheet" Feb. 26, 2007, In Brief). Currently, Oklahoma and Oregon each have a state law requring prescription-only access to pseudoephedrine products (2"The Tan Sheet" April 12, 2004, p. 4 and 3"The Tan Sheet" Aug. 22, 2005, p. 5)...
Meth Strategy Includes Tracking Success Of National Versus State Policies
The Bush Administration will monitor both national pseudoephedrine restrictions and stricter policies in states such as Oklahoma and Oregon to evaluate varying strategies for reducing methamphetamine abuse
Oregon Pseudoephedrine Law Requires Prescription Status By July 2006
Oregon's State Board of Pharmacy is required to make all adult pseudoephedrine products prescription-only under a law signed by Gov. Kulongoski Aug. 16